Linear bactenecin analogs with cell selectivity and anti-endotoxic activity

Journal of Peptide Science

Volumn 18, Issue 12, 2012, Pages 740-747

  Hai Nan, Yong ^a   Jacob, Binu ^a   Kim, Yangmee ^b   Yub Shin, Song ^a,c  

^a Chosun University   (South Korea)

^b Konkuk University   (South Korea)

^c Chosun University College of Medicine   (South Korea)

Author keywords

Anti endotoxin activity; Cell selectivity; Linear bactenecin analogs; Serum stability

Indexed keywords

AMINO ACID; BACTENECIN DERIVATIVE; BACTENECIN KL; BACTENECIN KLW; BACTENECIN KW; BACTENECIN L; BACTENECIN LW; BACTENECIN W; LIPOPOLYSACCHARIDE; NITRIC OXIDE; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTENECIN; CYCLOPEPTIDE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL CELL CULTURE; ANTIENDOTOXIC ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL INFECTION; CELL SELECTIVITY; CYTOKINE RELEASE; DISULFIDE BOND; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HEMOLYSIS; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN STABILITY; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; SEPTIC SHOCK; SERUM STABILITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; DRUG EFFECTS; DRUG STABILITY; ERYTHROCYTE; GRAM POSITIVE BACTERIUM; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MOUSE; SECRETION (PROCESS);

BACTERIA (MICROORGANISMS); BOVINAE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; DRUG STABILITY; ERYTHROCYTES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEMOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICROBIAL SENSITIVITY TESTS; NITRIC OXIDE; PEPTIDES, CYCLIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869195634     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2460     Document Type: Article

References (47)

1. Romeo D, Skerlavaj B, Bolognesi M, Gennaro, R. Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils. J. Biol. Chem. 1988; 263: 9573-9757.
2. Wu M, Hancock RE. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem. 1999; 274: 29-35.
3. Wu M, Hancock RE. Improved derivatives of bactenecin, a cyclic dodecameric antimicrobial cationic peptide. Antimicrob. Agents Chemother. 1999; 43: 1274-1276.
4. Rao AG. Conformation and antimicrobial activity of linear derivatives of tachyplesin lacking disulfide bonds. Arch. Biochem. Biophys. 1999; 361: 127-134.
5. Lee JU, Kang DI, Zhu WL, Shin SY, Hahm KS, Kim Y. Solution structures and biological functions of the antimicrobial peptide, arenicin-1, and its linear derivative. Biopolymers 2007; 88: 208-216.
6. Beutler B, Milsark IW, Cerami AC. Passive immunization against cathectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871.
7. Lehmann V, Freudenberg MA, Galanos, C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and d-galactosamine-treated mice. J. Exp. Med. 1987; 165: 657-663.
8. Morrison DC, Danner RL, Dinarello CA, Munford RS, Natanson C, Pollack M, Spitzer JJ, Ulevith RJ, Vogel SN, McSweegan E. Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future direction. J. Endotoxin Res. 1994; 1: 71-83.
9. Prins JM, Kuijper EJ, Mevissen ML, Speelman P, van Deventer SJ. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun. 1995; 63: 2236-2242.
10. Byl B, Clevenbergh P, Kentos A, Jacobs F, Marchant A, Vincent JL, Thys JP. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 804-807.
11. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 1995; 63: 1291-1297.
12. Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H, Tanaka S, Heumann D. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin. Diagn. Lab. Immunol. 2002; 9: 972-982.
13. Bommineni YR, Dai H, Gong YX, Soulages JL, Fernando SC, Desilva U, Prakash O, Zhang G. Fowlicidin-3 is an alpha-helical cationic host defense peptide with potent antibacterial and lipopolysaccharide-neutralizing activities. FEBS J. 2007; 274: 418-428.
14. Bhattacharjya S. De novo designed lipopolysaccharide binding peptides: structure based development of antiendotoxic and antimicrobial drugs. Curr. Med. Chem. 2010; 17: 3080-3093.
15. Mangoni ML, Shai Y. Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim. Biophys. Acta 2009; 1788: 1610-1619.
16. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988; 48: 4827-4833.
17. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Anal. Biochem. 1982; 126: 131-138.
18. Ma QQ, Shan AS, Dong N, Gu Y, Sun WY, Hu WN, Feng XJ. Cell selectivity and interaction with model membranes of Val/Arg-rich peptides. J. Pept. Sci. 2011; 17: 520-526.
19. Hu W, Lee KC, Cross TA. Tryptophans in membrane proteins: indole ring orientations and functional implications in the gramicidin channel. Biochemistry 1993; 32: 7035-7047.
20. Park K, Oh D, Shin SY, Hahm KS, Kim Y. Structural studies of porcine myeloid antibacterial peptide PMAP-23 and its analogues in DPC micelles by NMR spectroscopy. Biochem. Biophys. Res. Commun. 2002; 290: 204-212.
21. Eisenberg D. Three-dimensional structure of membrane and surface proteins. Annu. Rev. Biochem. 1984; 53: 595-623.
22. Eisenberg D, Schwarz E, Komaromy M, Wall R. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J. Mol. Biol. 1984; 179: 125-142.
23. Oren Z, Hong J, Shai Y. A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. J. Biol. Chem. 1997; 272: 14643-14649.
24. Wieprecht T, Dathe M, Beyermann M, Krause E, Maloy WL, MacDonald DL, Bienert M. Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. Biochemistry 1997; 36: 6124-6132.
25. Yan H, Li S, Sun X, Mi H, He B. Individual substitution analog of Mel(12-26), melittin's C-terminal 15-residue peptide: their antimicrobial and hemolytic actions. FEBS Lett. 2003; 554: 100-104.
26. Kim S, Kim SS, Lee BJ. Correlation between the activities of α-helical antimicrobial peptides and hydrophobicities represented as RP-HPLC retention times. Peptides 2005; 26: 2050-2056.
27. Lin QP, Zhou LF, Li NN, Chen YQ, Li BC, Cai YF, Zhang SQ. Lipopolysaccharide neutralization by the antibacterial peptide CM4. Eur. J. Pharmacol. 2008; 596: 160-165.
28. Zelezetsky I, Pacor S, Pag U, Papo N, Shai Y, Sahl HG, Tossi A. Controlled alteration of the shape and conformational stability of α-helical cell-lytic peptides: effect on mode of action and cell specificity. Biochem. J. 2005; 390: 177-188.
29. Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Hodges RS. Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J. Biol. Chem. 2005; 280: 12316-12329.
30. Fázio MA, Jouvensal L, Vovelle F, Bulet P, Miranda MT, Daffre S, Miranda A. Biological and structural characterization of new linear gomesin analogues with improved therapeutic indices. Biopolymers 2007; 88: 386-400.
31. Zhu WL, Song YM, Park Y, Park KH, Yang ST, Kim JI, Park IS, Hahm KS, Shin SY. Substitution of the leucine zipper sequence in melittin with peptoid residues affects self-association, cell selectivity, and mode of action. Biochim. Biophys. Acta 2007; 1768: 1506-1517.
32. Llenado RA, Weeks CS, Cocco MJ, Ouellette AJ. Electropositive charge in α-defensin bactericidal activity: functional effects of Lys-for-Arg substitutions vary with the peptide primary structure. Infect. Immun. 2009; 77: 5035-5043.
33. Kiyota T, Lee S, Sugihara G. Design and synthesis of amphiphilic α-helical model peptides with systematically varied hydrophobic-hydrophilic balance and their interaction with lipid- and bio-membranes. Biochemistry 1996; 35: 13196-13204.
34. Epand RF, Lehrer RI, Wang W, Maget-Dana R, Lelievre D, Epand RM. Direct comparison of membrane interactions of model peptides composed of only Leu and Lys residues. Biopolymers 2003; 71: 2-16.
35. Yang ST, Shin SY, Lee CW, Kim YC, Hahm KS, Kim JI. Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure. FEBS Lett. 2003; 540: 229-233.
36. Nan YH, Lee SH, Kim HJ, Shin SY. Mammalian cell toxicity and candidacidal mechanism of Arg- or Lys-containing Trp-rich model antimicrobial peptides and their d-enantiomeric peptides. Peptides 2010; 31: 1826-1831.
37. Dathe M, Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta 1999; 1462: 71-87.
38. Tossi A, Sandri L, Giangaspero A. Amphipathic, α-helical antimicrobial peptides. Biopolymers 2000; 55: 4-30.
39. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
40. Rosenfeld Y, Papo N, Shai, Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J. Biol. Chem. 2006; 281: 1636-1643.
41. Andra J, Koch MH, Bartels R, Brandenburg K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob. Agents Chemother. 2004; 48: 1593-1599.
42. Andra J, Lohner K, Blondelle SE, Jerala R, Moriyon I, Koch MH, Garidel P, Brandenburg K. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem. J. 2005; 385: 135-143.
43. Rosenfeld Y, Lev N, Shai Y. Effect of hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 2010; 49: 853-861.
44. Nan YH, Bang JK, Jacob B, Park IS, Shin SY. Prokaryotic selectivity and LPS-neutralizing activity of short antimicrobial peptides designed from the human antimicrobial peptide LL-37. Peptides 2012; 35: 239-247.
45. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of dl-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. 2003; 278: 21018-21023.
46. Meng H, Kumar K. Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J. Am. Chem. Soc. 2007; 129: 15615-15622.
47. Rotem S, Mor A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 2009; 1788: 1582-1592.